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Summary The relevance of P170-glycoprotein (P-gp) and multidrug resistance-associated protein (MRP) for the sensitivity to CPT-11 was
investigated in human malignant cell lines as well as in human tumour xenografts. In vitro, the P-gp-positive sublines BRO/mdrl.1
(transfected with MDR1) and 2780AD were slightly cross-resistant against carboxylesterase-activated CPT-11. Cross-resistance against SN-
38 was present in 2780AD cells, but not in BRO/mdrl.1 cells. The P-gp modulators BIBW22BS, verapamil and dexniguldipine partly reversed
the resistance against CPT-11 in the P-gp-positive sublines. BIBW22BS was the most effective modulator in the reversal of the resistance
against carboxylesterase-activated CPT-11 as well as against SN-38 in the 2780AD subline. In contrast to doxorubicin and vincristine, the
BRO/mdrl.1 xenografts were at least as sensitive to CPT-11 as the BRO xenografts. The 2780AD xenografts were slightly less sensitive than
the parent tumours, but there was no difference in topoisomerase I DNA unwinding activity. Therefore, the high retention of the multidrug-
resistant phenotype of 2780AD cells in vivo may be the cause of the low cross-resistance against CPT-11. The MRP-positive subline
GLC4/ADR was cross-resistant against carboxylesterase-activated CPT-11 and SN-38. GLC4/ADR cells, however, demonstrated a twofold
lower topoisomerase I activity than GLC4 cells. Cross-resistance against the camptothecin derivatives was not apparent in the MRP-
transfected subline of SW1573/Si. In conclusion, P-gp-positive cells show a low cross-resistance against CPT-11/SN38, which is only
apparent with high P-gp expression in vivo. MRP does not seem to play a role in the sensitivity to CPT-11.
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Cancer cells treated with cytostatic agents may become cross-
resistant against a range of drugs differing in structure and cell
target. 'Classical' multidrugresistance is associated with increased
expression ofthe MDR1 gene encoding a 170-kDa P-glycoprotein
(P-gp) (Ling et al, 1992). P-gp, an ATP-dependent transport
protein, is located in the plasma membrane and can extrude a
range ofhydrophobic natural drugs and cytostatic agents from the
cancer cells against a concentration gradient. As a result, the
presence of P-gp will induce drug resistance. However, another
mechanism may also contribute to multidrug resistance as
multidrug-resistant cells have been described that do not express
P-gp (Cole et al, 1991; Versantvoort et al, 1992). In one of these
non-P-gp cell lines, the H69AR small-cell lung cancer cell line,
Cole et al (1992) have found amplification of a novel gene, the
multidrug resistance-associated protein gene (MRP). Zaman et al
(1994) have reported that the multidrug resistance-associated
protein (MRP) also acts as a drug pump extruding hydrophobic
compounds from cells against the concentration gradient.
Although the drug resistance spectra associated with MRP and
MDR1 overexpression are remarkably similar, there are some
differences between P-gp and MRP and the drugs that they trans-
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port or interact with. Thus far, few data are available on the rele-
vance ofthese proteins for resistance against the topoisomerase I-
inhibiting camptothecins.
Camptothecin was isolated from the Chinese tree Campto-
theca acuminata, as has been described by Wall et al (1966).
Camptothecin shows strong anti-tumour activity against several
experimental tumours. In clinical trials in the early 1970s, it failed
to induce meaningful responses and proved to cause severe and
unpredictable myelosuppression, haemorrhagic cystitis and diar-
rhoea. The interest in camptothecin was revived in the late 1980s
after the identification ofthe enzyme topoisomerase I as the major
cellular target of camptothecin (Slichenmyer et al, 1993). Much
effort has been put into the synthesis of new water-soluble camp-
tothecin derivatives with higher anti-tumour activity and less
toxicity. This has led to the development of a novel water-soluble
derivative 7-ethyl-10[4-(1-piperidino)-1-piperidino]carbonyloxy
camptothecin (CPT-l 1). Although CPT-l 1 is very active in a wide
variety ofhuman tumour xenografts (Kunimoto et al, 1987), its in
vitro activity is rather poor. CPT-l 1 has to be converted into 7-
ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase to
exert its action (Kaneda et al, 1990; Tsuji et al, 1991). In a number
ofhuman colon cancer cell lines SN-38 has been found to be 130-
to 570-fold more active than CPT-1 1 (Jansen et al, 1997a). In the
clinic, CPT-l 1 has substantial activity against a range of tumour
types, particularly colorectal cancer, non-small-cell lung cancer
and cervical cancer (Slichenmyer et al, 1993).
The efficacy of camptothecin does not seem to be affected by
the presence of P-gp (Chen et al, 1991). It has been suggested,
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however, that some of the semisynthetic camptothecin analogues,
because of their positive charge at physiological pH, might be
affected by P-gp expression. This is based on the observation that
P-gp preferentially exports positively chargedhydrophobic natural
compounds (Zamora et al, 1988). Little is known on the role of
MRP in resistance against camptothecin analogues.
In the present experiments, we compared the activity ofCPT- 1I
and its metabolite SN-38 in P-gp- and MRP-positive sublines and
their parental cell lines. Several P-gp modulators were studied for
their ability to reverse the resistance against CPT-l1 and SN-38 in
vitro. The resistant sublines and parent cell lines were analysed for
differences in topoisomerase I gene expression and topoisomerase
I activity. In addition, we compared the efficacy ofCPT-l1 in nude
mice implanted with P-gp-positive xenografts with that in mice
bearing the parental P-gp-negative xenografts.
MATERIALS AND METHODS
Drugs
CPT-11 and SN-38 were kindly provided by Rhone-Poulenc
Rorer (Vitry surSeine, France). CPT-11 was available as a solution
of 20 mg ml-'. SN-38, as a powder, was dissolved in dimethyl-
sulphoxide (DMSO; Acros, Geel, Belgium) to a final concentra-
tion of 10 mm. Vincristine (Eli Lilly, Amsterdam, The
Netherlands) was purchased as a solution of 1 mg ml-'.
Doxorubicin (Farmitalia Carlo Erba, Nivelles, Belgium) was
dissolved in water at a concentration of 2 mg ml-'.
Carboxylesterase (3.1.1.1), isolated from porcine liver, was
purchased from Sigma (Zwijndrecht, The Netherlands).
BIBW22BS (from Dr Karl Thomae, Biberach an der Riss,
Germany) was first dissolved in 0.1 M hydrochloric acid and then
diluted in 0.9% sodium chloride to afinal concentration of2 mm at
pH 2.7. Verapamil (Knoll, Amsterdam, The Netherlands) was
provided as a solution of 2.5 mg ml-'. Dexniguldipine was
obtained from Byk Gulden, Konstanz, Germany; the powder was
dissolved in 0.5 ml of 5% polyethyleneglycol (PEG) 400 supple-
mented with 0.5 ml of 0.01 M hydrochloric acid to a final concen-
tration of 10 mm. Drugs and resistance modulators were further
diluted in tissue culture medium when investigated for their
antiproliferative effects in vitro.
Cell lines
Four pairs of human malignant cell lines were used. The P-gp-
positive subline BRO/mdr 1.1 (BRO/pFRmdrl.6 clone 1.1) was
obtained by transfection of the parent melanoma cell line BRO
with a full lengthMDR1 gene (Lincke et al, 1990). The P-gp-posi-
tive subline 2780AD ofovarian cancer cell line A2780 (Rogan et al,
1984) and the MRP-positive subline GLC4/ADR ofsmall-cell lung
cancer cell line GLC4 (Zaman et al, 1993) were selected by a step-
wise increase of the doxorubicin concentration in tissue culture
medium. The MRP-positive subline SW1573/S1 (MRP) was
obtained by transfection of the parent non-small-cell lung cancer
cell line SW1573/S1 with pRc/RSV-MRP DNA (Zaman et al,
1994). All cell lines were maintained in Dulbecco's modified
Eagle medium (Gibco, Breda, The Netherlands) supplemented
with 10% heat-inactivated fetal calf serum (Sebak, Aidenbach,
Germany), 50 IU ml-' penicillin and 50 ,ug ml-1 streptomycin
(Flow, Irvine, UK) in a humidified atmosphere containing 5%
carbon dioxide at 37°C. The resistant sublines were cultured in the
Table 1 IC50 of drugs [M (± s.e.m.)] in cell lines and multidrug-resistant
sublines
Cell line Doxorubicin RF Vincristine RFa
BRO 7.4 (+1.4) x 10-9 3.3 (+0.8) x 10-'
BRO/mdr1.1 6.6(1.1) x 1-7 89* 3.7(0.7) x 10-8 112*
A2780 3.4(0.2) x 1-9 3.0(0.1) x 10-'
2780AD 3.3 (± 0.6) x 10- 971 8.6 (± 1.8) x 107 2867*
GLC4 5.5 (1.6) x 10-9 5.0 (1.5) x1O-'
GLC4/ADR 3.7 (0.4) x 10-6 673* 4.3 (+1.2) x 10-10 0.9
SW1573/Si 4.8 (+ 0.6) x 10-9 3.6 (± 0.7) x 10-10
SW1573/S1 (MRP) 8.2 (+2.0) x 10-9 1.7 7.5 (+3.2) x 10-" 2.1
aRF, resistance factor expressed as the ratio of IC50 resistant cells to IC50
parent cells. *Significant, P< 0.001.
presence ofthe selecting drug until 3 days before the experiments.
All cell lines were free from Mycoplasma contamination as tested
regularly with the Mycoplasma TC rapid detection system with a
3H-labelled DNA probe from Gene-Probe (San Diego, CA, USA).
Proliferation inhibition experiments
Experiments to measure the inhibition ofproliferation were carried
out in 96-well microtitre plates and the percentage ofviable cells at
the end of the incubation period was determined using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT)
assay. In short, 3000-5000 cells per well in 100gl ofmedium were
plated and grown for 24 h, drugs (100 ,ul) were added and the cells
were cultured for an additional 96 h. Then the medium was
removed and 50 ,ul ofMTT (0.4 mg ml-') (Sigma) diluted in phos-
phate-buffered saline were added. The plates were incubated for
4 h andtheblue dye formed was dissolvedin 200gl ofDMSO. The
absorbance was measured at 540 nmusing aLabsystems Multiskan
Bichromatic plate reader (Labsystems, Helsinki, Finland). The
results were expressed as IC50 values, which are the concentrations
of the drug required to induce 50% inhibition of cell growth of
treated cells compared with the growth of control cells. The resis-
tance factor (RF) was expressed as the ratio oftheIC50 ofthe resis-
tant subline divided by the IC50 of the parent cell line. In control
cultures, cells grew exponentially during the incubation period. All
drug concentrations were tested in four replicate wells and the
experiments were performed at least four times.
In vivo sensitivity
Female nude mice (Hsd: athymic nude-nu) were purchased at the
age of6 weeks (Harlan CPB, Zeist, The Netherlands). The animals
were housed in filter-top cages under sterile conditions. Cages,
covers, bedding, food and water were sterilized and changed
weekly. Animal handling was done in a laminar down-flow hood.
For the animal experiments, permission was obtained from the
University Ethical Committee (project number Onc 94-01).
Xenografts were established from cell lines grown in tissue
culture medium. Mice were inoculated subcutaneously (s.c.) with
1 x 107 cells in both flanks (passage 1). Solid tumours arising at
the inoculation site were transferred as tissue fragments of2- to 3-
mm diameter through a small incision into both flanks of 8- to 10-
week-old mice. A previous study demonstrated the retention ofthe
multidrug-resistant phenotype in s.c. BRO/mdrl.1 xenografts
> 15 serial passages (Jansen et al, 1994). For the 2780- cells, a
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Table 2 IC50 of drugs [M (± s.e.m.)] in cell lines and multidrug-resistant sublines
Cell line CPT-11 RFU CPT-11+CE RFa SN-38 RFa
BRO 8.7(+1.5)x10-7 4.0(+1.0)x10-9 1.4(i0.9)x10-9
BRO/mdr1.1 4.6 (0.6)x 10-6 5.3* 3.1 (+0.9)x 10-8 7.8* 2.0(0.8) x 10-9 1.4
A2780 1.0 0(.2) x 106 7.7(2.0) x 10-9 1.8( 0.6) x 10-9
2780AD 1.4( 0.2) x 10 14* 1.6 (0.1) x 10-7 21 2.2 (0.6) x 10- 12*
GLC4 2.1 (0.4)x104 2.1 (0.5)x 10-8 2.1 (0.7)x 10-9
GLC4/ADR 4.1 (+0.7)x104 2.0* 2.3(+0.3)x10-7 11* 1.3(±0.4)x 10-8 6.2*
SW1573/S1 2.7 (±0.4) x 10-6 3.7 (± 1.2) x 10-i 1.9 (±0.5) x 10-8
SW1573/S1 (MRP) 3.9 (± 0.5) x 10-6 1.4 1.3 (± 0.4) x 10-7 3.5 1.5 (± 0.3) x 104 0.8
aRF, resistance factor expressed as the ratio of IC resistant cells to IC50 parent cells. *Significant, P < 0.05.
partial loss of multidrug resistance was found in passage 2 or
higher (unpublished data). Therefore, experiments with 2780AD
xenografts were carried out in passage 1. Tumour growth was
measured weekly in three dimensions with slide callipers by the
same observer. The tumour volume was expressed by the equation
length x width x height x 0.5 in mm3. Atthe start oftreatment (day
0), groups of5 or 6 tumour-bearing mice were formed to provide a
mean tumour volume ofapproximately 150 mm3 in each group.
For in vivo use, CPT-l1 was further diluted in 0.9% sodium
chloride to 2 mg ml. CPT-11 was administered intraperitoneally
on days 0, 1, 2, 3 and 4 as this schedule was more effective than a
weekly x 2 schedule (Jansen et al, 1997b). The 20 mg kg-' dose
was the maximum-tolerated dose of CPT-1 1 given daily x 5, as
based on the occurrence of a reversible weight loss of approxi-
mately 10% of the initial weight within the first 2 weeks after
day 0. Vincristine 1 mg kg-' and doxorubicin 8 mg kg-' given
intravenously weekly x 2 were the maximum-tolerated doses as
described earlier (Jansen et al, 1994).
For the evaluation of drug efficacy, the tumour volume was
expressed by the formula VT/VO, where VT is the volume on any
given day and V0 is the volume on day 0. The ratio of the mean
relative volume of treated tumours over that of control tumours
multiplied by 100% (T/C%) was assessed on each day ofmeasure-
ment. Anti-tumour effects were expressed as the maximum
percentage ofgrowth inhibition (100-T/C%).
Topoisomerase I gene expression
Total cellular RNA was isolated from exponentially growing cells
and from frozen xenograft tissue with RNAzol B (Campro
Scientific, Veenendaal, The Netherlands). a-32P-labelled RNA
complementary to topoisomerase I cDNA 703-bp sequence
(nucleotides 835-1538) (Juan et al, 1988) inserted into pGEM3
was transcribed from FokI-linearized DNA using T7 polymerase.
The RNAase protection assay was carried out as described
(Giaccone et al, 1995). In all experiments, a probe for y-actin was
included to control for RNA loading. The hybridized probe was
visualized after gel electrophoresis through a denaturing 6% acry-
lamide gel. For autoradiography, the gel was exposed at-70°C to a
Kodak BIOMAX MR film for 3 days. The amount of topoiso-
merase I mRNA relative to the amount ofy-actin was calculated by
densitometric scanning of the autoradiograms. Topoisomerase I
gene expression was determined at least twice in each cell line and
twice in four separate xenografts originating from a cell line.
Topoisomerase I activity
DNA topoisomerase I activity was determined using the ATP-inde-
pendent relaxation assay (Liu and Miller, 1981). Protein extracts
containing topoisomerase I enzymes were prepared from cell lines
and tumour specimens. Briefly, 1 x 107 cells or 50-100 mg offresh
Table 3 The influence of BIBW22BS (BIBW, 1 FM), verapamil (VPM, 10 jM) and dexniguldipine (DEX, 1 gM) on the antiproliferative effects of CPT-11,
CPT-11 + carboxylesterase (CE 1 igg ml-') and SN-38 in P-gp-positive BRO/mdrl.1 and 2780AD cells and parent cells
Drugs BRO BRO/mdr1.1 A2780 2780AD
M (± s.e.m.) RFO M (± s.e.m.) RFB M (± s.e.m.) RFa M (± s.e.m.) RFa
CPT-11 8.7(_1.5)x10-7 1 4.6(+0.6)x10-6 5.3 1.0(±0.2)x10-6 1 1.4(+0.2)x10-5 14
+ BIBW 1.0 (0.3) x 10- 1.1 1.4 (0.2) x 10-* 1.6 8.9 (1.5) x 10-7 0.9 2.5 (0.4) x 1046 1.5
+VPM 1.4 (0.4) x 10-6 1.6 1.7 (0.3) x 10-* 2.0 1.2 (0.3) x 10-6 1.2 4.3(0.5) x 10-6 4.3
+DEX 1.4(+0.2)x10-6 1.6 1.5(±0.4)x10--6 1.7 1.3(+0.3)x10-6 1.3 4.1 (1.2)x10-4 4.1
CPT-11 +CE 4.0 (1.0) x 10-9 1 3.1 (0.9) x 10-8 7.8 7.7(2.0) x 10-9 1 1.6(0.1) x 10-7 21
+ CE + BIBW 5.1 (1.7) x 10-9 1.3 2.2 (0.3) x 10-8 5.5 8.4 (3.7) x 10 9 1.1 3.6(1.2) x 10-8 4.7
+CE + VPM 4.2 (0.5) x 10-7 105 7.9 (3.0) x 10-7 198 4.0(0.6) x 10-7 52 3.4(0.9) x 10-6 442
+CE + DEX 3.4(1.7) x 10-9 0.9 3.2(1.5) x 10-8 8.0 1.9 (1.5) x 10-8 2.5 1.8(0.6) x 10-7 23
SN-38 1.4 (0.9) x 10-9 1 2.0 (0.8) x 10-9 1.4 1.8 (0.6) x 10-9 1 2.2 (0.6) x 10- 12
+ BIBW 1.9 (1.1) x 10-9 1.4 7.3(0.3) x 10- 0.5 1.9 (0.6) x 1-9 1.1 5.8(2.6) x 10-9 3.2
+ VPM 1.4 (0.8) x 10-9 1.0 1.0 (0.5) x 10-9 0.7 1.6(0.8) x 1-9 0.9 1.6(0.7) x 104 8.9
+ DEX 1.2 (0.9) x 10-9 0.9 1.3 (0.6) x 10-9 0.9 1.8 (0.7) x 10-9 1.0 1.8 (0.6) x 10-8 10
aRF, resistance factor expressed as the ratio of IC50 resistant cells to IC50 of parent cells treated with the camptothecin derivative alone. *Significantly
different (P < 0.01) with reference to the P-gp-positive subline treated with the camptothecin derivative alone.
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xenograft tissue was lysed on ice for 10 min in nuclear buffer
supplemented with Triton-X, 1 nM phenylmethylsulphonyl fluor-
ide (PMSF) (Merck, Amsterdam, The Netherlands) and 0.2 ,UM
dithiotreitol (DTT) (Sigma). Nuclear enzymes were extracted from
cell nuclei by incubation with nuclear buffer containing 0.4 M
sodium choloride for 30 min on ice. After centrifugation, the
enzyme solution was diluted with an equal volume of87% glycerol
and stored at -70°C for a maximum of 1 week. Topoisomerase I
activity was determined by measuring therelaxation ofsupercoiled
pBR329 plasmid DNA by incubation of serial dilutions of nuclear
extracts (1-100 jg) at 37°C for 30 min. Supercoiled and relaxed
DNA were separated on a 1% agarose gel by electrophoresis and
visualized by ethidium bromide staining. One unit of topoiso-
merase I activity was defined as the complete relaxation of 1gg of
supercoiled pBR329 plasmid DNA per min at 37°C. DNA topoiso-
merase I activity was measured at least four times in each cell line
and at least twice in four separate xenografts ofa cell line.
Statistics
Differences in drug sensitivity, topoisomerase I mRNA expression
and topoisomerase I activity between the multidrug-resistant
sublines and the parental cell lines were evaluated with the
Student's t-test.
RESULTS
Antiproliferative effects of CPT-11 in vitro
Most malignant cell lines and drug-resistant sublines described in
Table 1 have been characterized earlier for their sensitivity to
vincristine and doxorubicin (Jansen et al, 1994). Except for
vincristine in GLC4/ADR and SW1573/Sl (MRP), all sublines
were resistant against vincristine and doxorubicin. The resistance
factors (RFs) were highest in 2780AD cells and amounted to 2867
for vincristine and 971 for doxorubicin. The low resistance calcu-
lated for doxorubicin in SW1573/S1 (MRP) cells was not signifi-
cantly different from that in SW1573/S1 cells.
The antiproliferative effects ofCPT-l1 are listed in Table 2. The
efficacy ofCPT-11 was also measured in the presence ofan excess
of carboxylesterase (1 jg ml-1). Carboxylesterase increased the
antiproliferative effects ofCPT-l1 by 18- to 218-fold, whereas the
antiproliferative effects of SN-38 were 142- to 2300-fold higher
compared with those of CPT-l1 alone. BRO/mdrl.l, 278WAD
and GLC4/ADR were slightly cross-resistant to CPT-11 and
carboxylesterase-activated CPT-11. Cross-resistance to SN-38 was
present in the 2780AD and GLC4/ADR sublines, but not in the
BRO/mdrl.1 subline. In the SW1573/S1 (MRP) subline, cross-
resistance to CPT-11, carboxylesterase-activated CPT-11 and
SN-38 was not evident.
P-gp modulators
The effects of P-gp modulators on the reversal of resistance were
investigated intheP-gp-positive sublinesBRO/mdr. 1.1 and2780k" at
concentrations that were nottoxic, as established earlier (Jansen et al,
1994). The dipyridamole derivative BIBW22BS (1 gM) and the
calcium-channel blockers verapamil (10gM) and dexniguldipine
(1 gM) did not increase the antiproliferative effects of
carboxylesterase-activated CPT-l1 and SN-38 in the parent cell lines
BRO andA2780(Table 3). InBRO/mdrl.I and2780(W cells,theaddi-
tion ofthe modulators resulted in a slight, but significant, increase in
the antiproliferative effects of CPT-11. BIBW22BS had the highest
potency, but the reversal ofCPT-11 resistance was not complete. As
an illustration, the IC, (± s.e.m.) of CPT-11 in BRO/mdrl.l cells in
the presence of BIBW22BS was 1.4 (± 0.2) x 106M, while that in
BRO cells was 8.7 (± 1.5) x 10-7M (P < 0.05). The respective values
were 2.5 (± 0.4) x 106M in 2780AD cells and 1.0 (± 0.2) x 10--M
(P < 0.01) in A2780 cells. BIBW22BS was the only compound that
could partly reverse the resistance against carboxylesterase-activated
CPT-11 in 2780,, cells; theIC-, values were 3.6 (± 1.2) x 108M in
2780(D cells and 7.7 (± 2.0) x 10-9 M (P < 0.05) in A2780 cells.
Completereversalofresistance againstSN-38 was obtainedin2780(D
cells in the presence of BIBW22BS, as the IC-, values were not
significantly different; these were 5.8 (± 2.6) x 10-9 M in the 2780AD
cells and 1.8 (±0.6) x 10-9 M (P> 0.1) in the A2780 cells.
Verapamil decreased the antiproliferative effects ofCPT-l1 plus
carboxylesterase in all cell lines. It was found that verapamil at
10gM decreased the carboxylesterase activity, whereas
BIBW22BS (1 gM) and dexniguldipine (1 gM) did not affect the
enzyme activity (data not shown).
In vivo sensitivity
Previously, the activity of vincristine and doxorubicin has been
determined in the P-gp-positive xenografts and the corresponding
parent xenografts (Jansen et al, 1994). A summary of these data is
given in Table 4, showing the retention of the resistance against
vincristine and doxorubicin in the P-gp-positive tumours. In
contrast with the remarkable difference in sensitivity forvincristine
anddoxorubicin, there was no difference in sensitivity to CPT- 11 in
BRO/mdrl.1 xenografts compared with BRO xenografts. In both
experiments, the volume-doubling time of treated tumours was 27
days (Figure 1). The 2780(1 xenografts were slightly less sensitive
to CPT-11 than A2780 tumours; the volume-doubling times were 5
and 11 days respectively (Figure 1). The drug caused a reversible
weight loss of 10-11%; there were no toxic deaths.
Topoisomerase I gene expression and enzyme activity
The expected 84-bp transcript size fortopoisomerase I mRNA was
detected in all cell lines (Table 5). The topoisomerase I mRNA
Table 4 Human P-gp-negative and P-gp-positive xenografts and drug sensitivitya
Drug Dose (mg kg-') Days BRO (%) BRO/mdr1.1 (%) A2780 (%) 2780AD(%)
Doxorubicin 8 i.v. 0,7 87 (+ +) 55 (+) 80 (+ +) 0 (-)
Vincristine 1 i.v. 0,7 98 (+ +) 22 (-) 91 (+ +) 0 (-)
CPT-11 20 i.p. 0-4 96 (+ +) 99 (+ +) 81 (+ +) 64 (+)
a Chemosensitivity expressed as per cent growth inhibition: -, < 50%; +, > 50% < 75%; ++, 2 75%.
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Figure 1 Growth curves of BRO, BRO/mdrl.1, A2780 and 2780AD
xenografts in nude mice representing the mean relative volume of untreated
tumours (0) and that of tumours treated with CPT-11 20 mg kg-' i.p. daily x 5
(0). Arrows indicate the days of treatment and the bars represent s.e.m.
Table 5 Topoisomerase l(Topo 1) expression and activity in cell lines and
multidrug-resistant sublines
Material Topo I expressiona Topo I activityb
(mean ± s.e.m.) (mean ± s.e.m.)
Celllines
BRO 1 221 ±62
BRO/mdr1.1 0.90 ± 0.22 179 ± 55
A2780 1 171 ±24
2780AD 1.22 ±0.40 71 ± 8c
GLC4 1 150±11
GLC4/ADR 1.06 ±0.32 75±9c
SW1573/S1 1 146 ±30
SW1573/S1(MRP) 1.47 ± 0.48 83 ± 14
Xenografts
BRO 1 516±4
BRO/mdr1.1 1.39 ± 0.30 487 ± 34
A2780 1 307 ± 70
2780AD 1.00 ±0.10 456 ±53
aTopoisomerase I gene expression relative to theractin gene measured in at
least three different samples. Values are expressed as ratio of mRNA level in
parent cell line or xenograft. bTopoisomerase I activity (mU ig-1) measured in
at least four different samples. cSignificant difference in topoisomerase
activity between resistant cells and their parental cells (P< 0.01).
levels in the sublines were expressed as a ratio of the level in the
parent cell lines. The difference in sensitivity to CPT-l1 or SN-38
did notrelate with the extent oftopoisomerase I mRNA expression
in the P-gp-positive or the MRP-positive sublines and the parent
cell lines. Also in vivo, no difference in topoisomerase I mRNA
expression was observed between the P-gp-positive tumours and
the parental tumours.
Quantitation of the levels of ATP-independent topoisomerase I
DNA unwinding activity ofeach cell line is presented in Table 5.
The nuclear extracts from the multidrug-resistant sublines showed
a lower DNA-relaxing activity than that in the parent cell lines,
which was significant only in 278OW and GLC4/ADR cells.
The topoisomerase I activity was also determined in BRO,
BRO/mdrl.l, A2780 and 278OW xenografts. Between the P-gp-
positive and the parental xenografts, no significant differences
were found in topoisomerase I unwinding activity. The enzyme
activity in the xenografts was higherthan that in the corresponding
cell lines. The values in A2780 and 278OW xenografts did not
reflect the difference in topoisomerase I activity in the corre-
sponding cell lines.
DISCUSSION
Several mechanisms of resistance against topoisomerase I
inhibitors have been described: altered topoisomerase I gene
expression or structure, low protein levels ofthe enzyme, reduced
topoisomerase I activity, P-gp-mediated resistance and, for CPT-
11, reduced conversion ofthe drug to its active metabolite. In this
study, we investigated the relevance of the drug transporters P-gp
and MRP for the sensitivity to CPT-11, to carboxylesterase-
activated CPT-11 and to SN-38 in vitro and, for CPT-ll, in P-gp-
positive tumours in vivo to obtain more insight in these membrane
proteins accounting for CPT-11 resistance.
In vitro, the addition ofan excess ofcarboxylesterase to CPT- 1I
did not result in similar antiproliferative effects to those obtained
with SN-38. In a previous study in five unselected human colon
cancer cell lines, we also demonstrated a difference in efficacy
between carboxylesterase-activated CPT-11 and SN-38 (Jansen
et al, 1997a). Explanations may be that various nutrients in tissue
culture medium might inhibit the activation of the enzyme or that
the carboxylesterase extract from porcine liver is not a good
substitute for the endogenous carboxylesterase converting CPT-11
in other species. Of interest, however, regardless of the dose of
CPT-11 administered to patients, the proportion of SN-38 formed
was low and varied between 1.3% and 5.8% (Abigerges et al,
1995). An explanation may be the complicated metabolic pathway
ofCPT-11, as atleast 15 metabolites have been detected in the bile
of a patient (Lokiec et al, 1996). By adding an excess of
carboxylesterase in vitro it is possible that, apart from SN-38,
other less active metabolites are being formed.
In the P-gp-positive sublines, cross-resistance against CPT-11
was even more pronounced in the presence of exogenous
carboxylesterase. In 2780O" cells, SN-38 was also cross-resistant,
but this was not the case in BRO/mdrl.1 cells. Hendriks et al
(1992) have shown for topotecan and Mattem et al (1993) for
topotecan, SN-38 and 9-aminocamptothecin that drug accumula-
tion and cytotoxicity were reduced in P-gp-positive CHRC5 cells
relative to the parental AuxB1 cells. It has been suggested that the
positive charge ofthe camptothecin analogues topotecan and CPT-
11 could affect the efflux of these compounds by an increased
binding affinity to P-gp (Chen et al, 1991). Mattem et al (1993),
however, have demonstrated that a positive charge was not
required for P-gp-mediated drug resistance, as 9-aminocampto-
thecin and SN-38, which are uncharged at physiological pH, were
cross-resistant in CHRC5 cells. In ourexperiments, the low level of
cross-resistance of SN-38 in the 2780A1 cells could indeed be due
to P-gp, which is highly overexpressed in these cells, while the
BRO/mdrl.I cells express a less intense multidrug-resistant
phenotype. Another explanation may be that the BRO/mdrl.I
subline, transfected with theMDR1 gene, has a well-defined single
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mechanism of multidrug resistance (P-gp overexpression),
whereas the 2780AD subline was selected by a stepwise increasing
concentration ofdoxorubicin. This provides an in vitro P-gp-medi-
ated resistance model, which could also contain a mechanism of
resistance that affects the sensitivity to SN-38. Unlike the
BRO/mdrl.1 cells, the 2780AD cells showed a reduced topoiso-
merase I activity compared with that of the parental cells. The P-
gp-positive cells, however, were far less cross-resistant against the
camptothecins than the typical multidrug-resistance compounds,
such as vincristine and doxorubicin.
The addition of the P-gp modulators BIBW22BS, verapamil
and dexniguldipine reversed the resistance against CPT-1 1 in the
P-gp-positive sublines. Hendricks et al (1992) have shown that
incubation with quinidine or with verapamil, modulators of P-gp-
mediated multidrug resistance, increased both the accumulation
and the cytotoxicity of topotecan. In a previous study, we have
demonstrated that BIBW22BS had a higher potency in the
modulation ofP-gp than verapamil, bepridil or flunarizine in vitro
(Jansen et al, 1994). Indeed, the relatively high resistance against
SN-38 in the 2780AD cell line was circumvented only by
BIBW22BS.
In vivo, we found an almost equal growth inhibition induced by
CPT-l1 in BRO and BRO/mdrl.1 xenografts. Other investigators
have also demonstrated that camptothecins have therapeutic
activity in multidrug-resistant tumours in vivo. Houghton et al
(1993) have reported for topotecan and CPT-11 that the efficacy
was similar in both human rhabdomyosarcoma parental tumours
and P-gp-positive Rhl21VCR and Rh18/VCR tumours. Similar
results were obtained by Tsuruo et al (1988), who have demon-
strated an almost equal activity of CPT-l1 in P388 leukaemia-
bearing mice and in mice bearing P388 cells resistant against
vincristine and doxorubicin. Our 2780AD tumours were less sensi-
tive to CPT-11 than the A2780 tumours. In both BRO/mdrl.1 and
2780AD xenografts, topoisomerase I activity was similar to that in
the parental xenografts. A likely explanation for the lower sensi-
tivity of 2780AD tumours to CPT-ll/SN-38 is that 2780AD cells
grown in vivo retain a highly resistant phenotype to drugs affected
by P-gp (Table 4). The clinical relevance of this finding is not
important, as P-gp expression in patients' tumours is much lower
than in 2780AD cells.
Another protein that may affect drug sensitivity is the
more recently characterized MRP. Cross-resistance against
carboxylesterase-activated CPT-11 and SN-38 was observed in
GLC4/ADR cells, whereas in the SW1573/Sl(MRP) cells cross-
resistance was not evident. Hasegawa et al (1995) have demon-
strated that T24/ADM-1 and T24/ADM-2 human bladder cancer
cells, both overexpressing the MRP gene, were not cross-resistant
against CPT-11, whereas the cells showed cross-resistance against
doxorubicin and etoposide. Thus, it is probable that CPT-1 1 is not
a substrate for MRP and the cross-resistance in the GLC4/ADR
subline might be related to other factors of relevance for sensi-
tivity to CPT-l1. Indeed, GLC4/ADR cells showed a twofold
reduction in topoisomerase I activity compared with the enzyme
activity in the parental cells. It is uncertain whether the
SW1573/Sl(MRP) subline provides a good model for MRP-
mediated drug resistance, as we did not find a significant differ-
ence in sensitivity to doxorubicin and vincristine between the
SW1573/Sl(MRP) cells and the parental cells. Zaman et al (1994)
have also reported a modest cross-resistance against doxorubicin
and vincristine of 2.7- and 5.3-fold, respectively, in the
SW1573/S1(MRP) cells.
A relation between the topoisomerase I gene expression and the
sensitivity to carboxylesterase-activated CPT-11 or SN-38 could
be expected. In this respect, Niwa et al (1995) have found a corre-
lation between topoisomerase I mRNA and the sensitivity to CPT-
11 in various human cancer cell lines, which displayed natural
differences in sensitivity to CPT-11. Our group (Jansen et al,
1997a) as well as the group of Goldwasser et al (1995) have
demonstrated that there was no relation between topoisomerase I
mRNA expression and sensitivity to camptothecins. In the present
study, the extent oftopoisomerase I mRNA expression was similar
in the multidrug-resistant sublines and the parental cell lines,
which did not reflect the differences in sensitivity to CPT-11 and
SN-38. Consistent with our finding, the expression ofthe topoiso-
merase I gene in the multidrug-resistant KK47/ADM and
T24NVCR human bladder cancer sublines was similar to that in the
parental cell lines, although there was an approximately threefold
resistance against CPT-11 (Hasegawa et al, 1995).
As a relationship seems to be present between the cellular topo-
isomerase I activity and the sensitivity to camptothecins, it would
appear that resistant cells have a reduced topoisomerase I activity.
In the panel of five unselected human colon cancer cell lines, we
have indeed found a positive correlation between the DNA topo-
isomerase I activity and the sensitivity to carboxylesterase-acti-
vated CPT-l1 and to SN-38 (Jansen et al, 1997a). Goldwasser et al
(1995) have demonstrated a positive correlation between campto-
thecin sensitivity and the amount of drug-stabilized cleavable
complexes. Reduction of topoisomerase I activity has also been
described in a number ofcell lines with acquired resistance against
camptothecins (Chang et al, 1992; Woessner et al, 1992). In the
two sublines 2780AD and GLC4/ADR with acquired resistance
against doxorubicin, we found a2- to 2.5-fold lowertopoisomerase
I activity, which may partly explain cross-resistance against
carboxylesterase-activated CPT-11 and SN-38 in vitro. Reduced
enzyme activity without decreased levels of topoisomerase I
mRNA in camptothecin-resistant cells may be caused by a gene
mutation or may be the result ofrearrangement, deletion or hyper-
methylation of one of the topoisomerase I alleles (Gupta et al,
1995). The reason for areduced topoisomerase I activity in 2780AD
and GLC4/ADR cells remains to be established.
In conclusion, thepresence ofP-gp was related to alow degree of
cross-resistance to CPT- 1I and to SN-38 in vitro. In vivo, the contri-
bution of P-gp to the resistance against CPT-1 1 appeared to be
dependent on the extent of overexpression. Nevertheless, CPT-11
showed superior anti-tumour activity in P-gp-positive xenografts
compared with vincristine and doxorubicin. The presence of MRP
did not seem to affect the sensitivity to CPT-1 1 and SN-38 in vitro.
Therefore, CPT-l1 should be considered as a potentially effective
agent in the treatment ofmultidrug-resistant tumours.
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